WO2003006154A3 - Protein design automation for designing protein libraries with altered immunogenicity - Google Patents

Protein design automation for designing protein libraries with altered immunogenicity Download PDF

Info

Publication number
WO2003006154A3
WO2003006154A3 PCT/US2002/000165 US0200165W WO03006154A3 WO 2003006154 A3 WO2003006154 A3 WO 2003006154A3 US 0200165 W US0200165 W US 0200165W WO 03006154 A3 WO03006154 A3 WO 03006154A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
designing
design automation
libraries
altered immunogenicity
Prior art date
Application number
PCT/US2002/000165
Other languages
French (fr)
Other versions
WO2003006154A2 (en
Inventor
Arthur Chirino
Bassil I Dahiyat
John Desjarlais
Original Assignee
Xencor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2001/021823 external-priority patent/WO2002005146A2/en
Application filed by Xencor Inc filed Critical Xencor Inc
Priority to JP2006515515A priority Critical patent/JP2007520423A/en
Priority to CA002452824A priority patent/CA2452824A1/en
Priority to EP02784886A priority patent/EP1572345A3/en
Publication of WO2003006154A2 publication Critical patent/WO2003006154A2/en
Publication of WO2003006154A3 publication Critical patent/WO2003006154A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/473—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used alpha-Glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to the use of a variety of computational methods for modulating the immunogenicity of proteins by identifying and then altering potential amino acid sequences that elicit an immune response in a host organism. In particular, proteins will be screened for MHC binding sequences, T cell epitopes and B cell epitopes.
PCT/US2002/000165 2001-07-10 2002-01-04 Protein design automation for designing protein libraries with altered immunogenicity WO2003006154A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2006515515A JP2007520423A (en) 2001-07-10 2002-01-04 Protein design automation to design modified immunogenic protein libraries
CA002452824A CA2452824A1 (en) 2001-07-10 2002-01-04 Protein design automation for designing protein libraries with altered immunogenicity
EP02784886A EP1572345A3 (en) 2001-07-10 2002-01-04 Protein design automation for designing protein libraries with altered immunogenicity

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
USPCT/US01/21823 2001-07-10
PCT/US2001/021823 WO2002005146A2 (en) 2000-07-10 2001-07-10 Method for disigning protein libraries with altered immunogenicity
US09/903,378 2001-07-10
US09/903,378 US20020119492A1 (en) 2000-07-10 2001-07-10 Protein design automation for designing protein libraries with altered immunogenicity

Publications (2)

Publication Number Publication Date
WO2003006154A2 WO2003006154A2 (en) 2003-01-23
WO2003006154A3 true WO2003006154A3 (en) 2005-10-13

Family

ID=26680528

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/000165 WO2003006154A2 (en) 2001-07-10 2002-01-04 Protein design automation for designing protein libraries with altered immunogenicity

Country Status (3)

Country Link
JP (1) JP2007520423A (en)
CA (1) CA2452824A1 (en)
WO (1) WO2003006154A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852586B2 (en) 2004-11-12 2014-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
US8883147B2 (en) 2004-10-21 2014-11-11 Xencor, Inc. Immunoglobulins insertions, deletions, and substitutions
US8937158B2 (en) 2003-03-03 2015-01-20 Xencor, Inc. Fc variants with increased affinity for FcγRIIc
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020048772A1 (en) 2000-02-10 2002-04-25 Dahiyat Bassil I. Protein design automation for protein libraries
US7315786B2 (en) 1998-10-16 2008-01-01 Xencor Protein design automation for protein libraries
EP1432980A4 (en) * 2001-08-10 2006-04-12 Xencor Inc Protein design automation for protein libraries
US7381792B2 (en) 2002-01-04 2008-06-03 Xencor, Inc. Variants of RANKL protein
JP2005530482A (en) 2002-01-04 2005-10-13 ゼンコー・インコーポレイテッド Dominant negative proteins and their use
AU2003207232A1 (en) 2002-02-06 2003-09-02 Japan Energy Corporation Method for preparing hydrogenation purification catalyst
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
EP1581904A2 (en) * 2003-01-08 2005-10-05 Xencor, Inc. Novel proteins with altered immunogenicity
WO2005014641A2 (en) * 2003-07-09 2005-02-17 Xencor, Inc. Ciliary neurotrophic factor variants
US8399618B2 (en) 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
EP1695252A2 (en) * 2003-12-08 2006-08-30 Xencor, Inc. Protein engineering with analogous contact environments
WO2005113598A2 (en) * 2004-05-21 2005-12-01 Xencor, Inc. Tnf super family members with altered immunogenicity
WO2005113599A1 (en) * 2004-05-21 2005-12-01 Xencor, Inc. C1q family member proteins with altered immunogenicity
JP4660756B2 (en) * 2005-03-25 2011-03-30 国立大学法人徳島大学 Immobilization of protein / peptide on diamond chip
US20070184487A1 (en) * 2005-07-12 2007-08-09 Baynes Brian M Compositions and methods for design of non-immunogenic proteins
WO2007041635A2 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
WO2009086320A1 (en) 2007-12-26 2009-07-09 Xencor, Inc Fc variants with altered binding to fcrn
JP5435539B2 (en) * 2008-09-29 2014-03-05 独立行政法人産業技術総合研究所 Activating peptide of antibody-producing cells
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
NZ702084A (en) * 2012-05-25 2016-09-30 Bayer Healthcare Llc System and method for predicting the immunogenicity of a peptide
EP3433779A4 (en) * 2016-03-24 2019-12-25 Baker, Brian, M. Biomolecule design model and uses thereof
JP7347113B2 (en) * 2019-10-21 2023-09-20 富士通株式会社 Method for searching for modified sites in peptide molecules, searching device, and program

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
OSTANKOVITCH M ET AL: "A PARTIALLY MODIFIED RETRO-INVERSO PSEUDOPEPTIDE MODULATES THE CYTOKINE PROFILE OF CTL SPECIFIC FOR AN INFLUENZA VIRUS EPITOPE", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, 1998, pages 200 - 208, XP002933305, ISSN: 0022-1767 *
SCHUELER-FURMAN O ET AL: "Knowledge-based structure prediction of MHC class I bound peptides: a study of 23 complexes.", FOLDING & DESIGN. 1998, vol. 3, no. 6, 1998, pages 549 - 564, XP002317413, ISSN: 1359-0278 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8937158B2 (en) 2003-03-03 2015-01-20 Xencor, Inc. Fc variants with increased affinity for FcγRIIc
US8883147B2 (en) 2004-10-21 2014-11-11 Xencor, Inc. Immunoglobulins insertions, deletions, and substitutions
US8852586B2 (en) 2004-11-12 2014-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
US8883973B2 (en) 2004-11-12 2014-11-11 Xencor, Inc. Fc variants with altered binding to FcRn
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn

Also Published As

Publication number Publication date
CA2452824A1 (en) 2003-01-23
WO2003006154A2 (en) 2003-01-23
JP2007520423A (en) 2007-07-26

Similar Documents

Publication Publication Date Title
WO2003006154A3 (en) Protein design automation for designing protein libraries with altered immunogenicity
WO2002005146A3 (en) Method for disigning protein libraries with altered immunogenicity
WO2003052055A3 (en) Egvii endoglucanase and nucleic acids encoding the same
WO2003052056A3 (en) Egviii endoglucanase and nucleic acids encoding the same
WO2004099370A3 (en) NOVEL BACILLUS mHKcel CELLULASE
HK1061566A1 (en) Proteins producing an altered immunogenic response and methods of making and using the same
WO2003052057A3 (en) Egvi endoglucanase and nucleic acids encoding the same
WO2003027306A3 (en) Bgl3 beta-glucosidase and nucleic acids encoding the same
WO2004063963A3 (en) Novel proteins with altered immunogenicity
WO2003068941A3 (en) Modulation of immune response by non-peptide binding stress response polypeptides
IL169804A (en) 254p1d6b proteins, nucleic acids encoding the same, processes for producing the same, antibodies binding thereto and uses thereof
WO2002062999A3 (en) Proteins and nucleic acids encoding same
WO2004097001A3 (en) Novel bacillus 029cel cellulase
WO2003072746A3 (en) Subtilisin carlsberg proteins with reduced immunogenicity
WO2004035742A3 (en) Sets of digital antibodies directed against short epitopes, and methods using same
WO2002059315A3 (en) Human nucleic acids and polypeptides and methods of use thereof
WO2002046409A3 (en) Proteins and nucleic acids encoding same
ZA200006309B (en) A polypeptide comprising the amino acid of an n-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof.
WO2000063385A3 (en) Nucleic acid immunization
WO2005049639A3 (en) Compositions and methods for protein isolation
EP1515738A4 (en) Scytovirins and related conjugates, fusion proteins, nucleic acids, vectors, host cells, compositions, antibodies and methods of using scytovirins
WO2002085922A3 (en) Proteins and nucleic acids encoding same
HUP0102306A3 (en) A polypeptide comprising the amino acid of an n-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof
WO2002090500A3 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
WO2005005465A3 (en) Methods and compositions to enhance immune responses via recall antigens

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2452824

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002306402

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006515515

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002784886

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002784886

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002784886

Country of ref document: EP